ProKidney (NASDAQ:PROK) Announces Earnings Results

ProKidney (NASDAQ:PROK) released its quarterly earnings results on Monday. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.03), Zacks reports. The business had revenue of $0.08 million during the quarter.

ProKidney Trading Up 5.7 %

Shares of PROK stock opened at $1.04 on Tuesday. The company has a market capitalization of $303.33 million, a price-to-earnings ratio of -1.89 and a beta of 1.38. The firm has a 50-day moving average price of $1.48 and a 200 day moving average price of $1.77. ProKidney has a twelve month low of $0.94 and a twelve month high of $4.44.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.